Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window.

@article{Rudolph2016ChemicallyDG,
  title={Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window.},
  author={Joachim Rudolph and Lesley J. Murray and Chudi O Ndubaku and Thomas O'Brien and Elizabeth M. Blackwood and Weiru Wang and Ignacio Aliagas and Lewis Gazzard and James J Crawford and Joy Drobnick and Wendy S. C. Lee and Xianrui Zhao and Klaus P. Hoeflich and David A. Favor and Ping Dong and Haiming Zhang and Christopher E Heise and Angela Jinsook Oh and Christy C. Ong and H. S. La and Paroma Chakravarty and Connie Chan and Diana Jakubiak and Jennifer A Epler and Sreemathy Ramaswamy and Roxanne Vega and G. C. Cain and Dolores D{\'i}az and Yu Min Zhong},
  journal={Journal of medicinal chemistry},
  year={2016},
  volume={59 11},
  pages={5520-41}
}
p21-activated kinase 1 (PAK1) has an important role in transducing signals in several oncogenic pathways. The concept of inhibiting this kinase has garnered significant interest over the past decade, particularly for targeting cancers associated with PAK1 amplification. Animal studies with the selective group I PAK (pan-PAK1, 2, 3) inhibitor G-5555 from the… CONTINUE READING